Katharina Lemberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katharina Lemberg has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Friedhelm Hildebrandt
Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, USA
4 shared publications - Ken Saida
Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, USA
4 shared publications Daanya Salmanullah
Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, USA
3 shared publications- Florian Buerger
Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, USA
3 shared publications Ronen Schneider
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
3 shared publicationsShirlee Shril
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
3 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10654
Recessive variants in the intergenic NOS1AP-C1orf226 locus cause monogenic kidney disease responsive to anti-proteinuric treatment
In genetic disease, an accurate expression landscape of disease genes and faithful animal models can facilitate genetic diagnoses and therapeutic advances respectively. Previously, we found that variants in NOS1AP, the gene that encodes nitric oxide synthase 1 adaptor protein, cause monogenic nephrotic syndrome. Here, we determine that an intergenic splice product of NOS1AP/Nos1ap and neighboring C1orf226/Gm7694, which prevents NOS1AP from binding to nitric oxide synthase 1, is the predominant isoform in mammalian kidney transcriptional and proteomic data. Gm7694−/− mice, whose allele exclusively disrupts the intergenic product, develop nephrotic syndrome phenotypes. In two male human subjects with nephrotic syndrome, we identify causative NOS1AP splice variants, including one predicted to abrogate intergenic splicing but initially misclassified as benign based on the canonical transcript. Finally, by modifying genetic background, we generate a faithful mouse model of NOS1AP-associated monogenic nephrotic syndrome that responds to anti-proteinuric treatment.
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10654
Open AccessRecessive variants in the intergenic NOS1AP-C1orf226 locus cause monogenic kidney disease responsive to anti-proteinuric treatment
In genetic disease, an accurate expression landscape of disease genes and faithful animal models can facilitate genetic diagnoses and therapeutic advances respectively. Previously, we found that variants in NOS1AP, the gene that encodes nitric oxide synthase 1 adaptor protein, cause monogenic nephrotic syndrome. Here, we determine that an intergenic splice product of NOS1AP/Nos1ap and neighboring C1orf226/Gm7694, which prevents NOS1AP from binding to nitric oxide synthase 1, is the predominant isoform in mammalian kidney transcriptional and proteomic data. Gm7694−/− mice, whose allele exclusively disrupts the intergenic product, develop nephrotic syndrome phenotypes. In two male human subjects with nephrotic syndrome, we identify causative NOS1AP splice variants, including one predicted to abrogate intergenic splicing but initially misclassified as benign based on the canonical transcript. Finally, by modifying genetic background, we generate a faithful mouse model of NOS1AP-associated monogenic nephrotic syndrome that responds to anti-proteinuric treatment.
- Open Access
A kidney specific mouse model to study the effects of in vivo induction of Yamanaka factors
Introduction: Maladaptive repair after acute kidney injury (AKI) leads to fibrosis and chronic kidney disease (CKD). Improving the resilience and stimulating tissue repair after injury is crucial to prevent AKI-to-CKD transition. Using a combination of transcription factors (Yamanaka factors Oct4, Klf4 and Sox2, “OKS” ) to partially reprogram tissues and enhance regeneration in vivo , could be a promising approach as shown by amelioration after various organ injury, yet not investigated for AKI to date. Methods: We used a ubiquitously and kidney-specific transgenic mouse model to investigate OKS expression in kidney. In a kidney-specific model using Pax8-Cre, we then induced AKI via aristolochic acid (AA), simultaneously expressing OKS to determine potential protective effects after kidney injury. Results: We show that a ubiquitously expressing OKS -mouse model was not suitable due to toxic effects and limited kidney expression. In the Pax8 -Cre mouse model, we observed expression almost exclusively to proximal tubules. While induction for more than 3 days caused dysplastic tumor formation, an induction regimen limited to 3 days was not able to improve phenotypic outcome after AA-injury. Conclusion: Partial reprogramming of the kidney using OKS is feasible; however, it requires a delicate balance to the risk of oncogenic transformation. Determine a dose that effectively promotes repair without crossing the threshold into harmful effects remains a major challenge, posing significant safety concerns for translating the approach to humans in the near future.
Open AccessA kidney specific mouse model to study the effects of in vivo induction of Yamanaka factors
Introduction: Maladaptive repair after acute kidney injury (AKI) leads to fibrosis and chronic kidney disease (CKD). Improving the resilience and stimulating tissue repair after injury is crucial to prevent AKI-to-CKD transition. Using a combination of transcription factors (Yamanaka factors Oct4, Klf4 and Sox2, “OKS” ) to partially reprogram tissues and enhance regeneration in vivo , could be a promising approach as shown by amelioration after various organ injury, yet not investigated for AKI to date. Methods: We used a ubiquitously and kidney-specific transgenic mouse model to investigate OKS expression in kidney. In a kidney-specific model using Pax8-Cre, we then induced AKI via aristolochic acid (AA), simultaneously expressing OKS to determine potential protective effects after kidney injury. Results: We show that a ubiquitously expressing OKS -mouse model was not suitable due to toxic effects and limited kidney expression. In the Pax8 -Cre mouse model, we observed expression almost exclusively to proximal tubules. While induction for more than 3 days caused dysplastic tumor formation, an induction regimen limited to 3 days was not able to improve phenotypic outcome after AA-injury. Conclusion: Partial reprogramming of the kidney using OKS is feasible; however, it requires a delicate balance to the risk of oncogenic transformation. Determine a dose that effectively promotes repair without crossing the threshold into harmful effects remains a major challenge, posing significant safety concerns for translating the approach to humans in the near future.
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101280
Expanding the spectrum of novel candidate genes using trio exome sequencing and identification of monogenic cause in 27.5% of 320 families with steroid-resistant nephrotic syndrome
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101280
Open AccessExpanding the spectrum of novel candidate genes using trio exome sequencing and identification of monogenic cause in 27.5% of 320 families with steroid-resistant nephrotic syndrome
- Open Access
- 1 September 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (5) , 101111
Exome sequencing identifies a likely causative variant in 53% of families with ciliopathy-related features on renal ultrasound after excluding NPHP1 deletions
- 1 September 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (5) , 101111
Open AccessExome sequencing identifies a likely causative variant in 53% of families with ciliopathy-related features on renal ultrasound after excluding NPHP1 deletions
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (5) , F780-F791
Quantitative phenotyping of Nphs1 knockout mice as a prerequisite for gene replacement studies
To evaluate potential, even subtle molecular, therapeutic effects of gene replacement therapy (GRT) in a mouse model, prior rigorous quantifiable and reproducible disease phenotyping is necessary. Here, we, therefore, describe such a phenotyping effort in nephrin ( Nphs1) knockout mice to establish the basis for GRT for congenital nephrotic syndrome. We believe that our findings set an important basis for upcoming/ongoing gene therapy approaches in the field of nephrology, especially for monogenic nephrotic syndrome.
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (5) , F780-F791
Quantitative phenotyping of Nphs1 knockout mice as a prerequisite for gene replacement studies
To evaluate potential, even subtle molecular, therapeutic effects of gene replacement therapy (GRT) in a mouse model, prior rigorous quantifiable and reproducible disease phenotyping is necessary. Here, we, therefore, describe such a phenotyping effort in nephrin ( Nphs1) knockout mice to establish the basis for GRT for congenital nephrotic syndrome. We believe that our findings set an important basis for upcoming/ongoing gene therapy approaches in the field of nephrology, especially for monogenic nephrotic syndrome.